๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Endometrial Neoplasms
Clinical trial register · China

Endometrial Neoplasms Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 8 Jinan 4 Guangzhou 4 Wuhan 4 Shanghai 4
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing8 Jinan4 Guangzhou4 Wuhan4 Shanghai4
All 23 locations
Target enrolment
to

Endometrial Neoplasms trials in China

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
NCT07714070Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance
Peking University People's Hospital
Phase 2
48
Beijing
2026-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Beijing, Tianjin
2025-08-06
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 1
240
Chengdu, Shanghai, Wuhan
2025-07-28
Recruiting
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
NCT06532539Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2024-06-13
Not yet open
MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer
NCT06126393Endometrial Neoplasms
Fujian Cancer Hospital
Observational
350
Fuzhou
2024-01-01
Active, closed
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
NCT05869123Uterine Cervical Neoplasm, Endometrial Neoplasms
Peking Union Medical College Hospital
Phase 1/2
17
Beijing
2022-10-20
Recruiting
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
NCT06379113Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
Xiaojun Chen
Phase 2/3
29
Shanghai
2022-07-13
Recruiting
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
NCT05316935Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance
Xiaojun Chen
Phase 2/3
80
Shanghai
2022-07-13
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
AstraZeneca
Phase 3
805
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangdong, Guangzhou
2020-05-05
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
Eisai Inc.
Phase 1/2
301
Beijing, Changchun, Fuzhou, Guangzhou, Jinan, Kunming, Shanghai, Shenzhen
2019-07-11
Recruiting
Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer
NCT05945407Endometrial Neoplasms, Endometrial Neoplasm Malignant, Endometrial Neoplasm Malignant Stage I, Carcinoma, Endometrioid
Peking University People's Hospital
Not applicable
57
Beijing
2016-08-01
Active, closed
The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma
NCT01820884Endometrial Neoplasms
Ding Ma
Not applicable
240
Wuhan, Jinan, Hangzhou
2012-11
Active, closed
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
NCT01820858Endometrial Neoplasms
Ding Ma
Phase 3
300
Wuhan, Jinan, Hangzhou
2012-11
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/endometrial-neoplasms

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies listing the condition Endometrial Neoplasms.

How many Endometrial Neoplasms trials are recruiting in China?

6 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Endometrial Neoplasms), 15 studies
PhaseStudiesRecruitingShare
Phase 34026.7%
Not applicable2113.3%
Phase 12213.3%
Phase 1/22013.3%
Phase 22113.3%
Phase 2/32213.3%
Observational106.7%

Most active sponsors

Lead sponsors with the most studies (Endometrial Neoplasms)
Lead sponsorStudiesRecruiting
Ding Ma20
Eli Lilly and Company22
Merck Sharp & Dohme LLC20
Peking University People's Hospital21
Xiaojun Chen22
AstraZeneca10
Eisai Inc.10
Fujian Cancer Hospital10
Peking Union Medical College Hospital10
Shandong Cancer Hospital and Institute11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.